Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the primary intracellular cation, essential for nerve impulse transmission, muscle contraction, and acid-base balance. Replacement therapy with potassium chloride corrects hypokalemia by increasing extracellular potassium concentration, restoring normal membrane potential and cellular function.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; rate not to exceed 10 mEq/hour (10 mmol/hour) or 0.02 mEq/kg/min (0.02 mmol/kg/min) for adults; maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein; typical dose 20-40 mEq (20-40 mmol) per day.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal half-life: 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 12-24 hours, increasing risk of hyperkalemia.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal: >90% of potassium chloride is excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal/biliary elimination is negligible (<2%) under normal renal function.
Category C
Category A/B
Electrolyte
Electrolyte